First and final report of a phase II study of the poly(ADP-ribose) polymerase (PARP) inhibitor, AGO14699, in combination with temozolomide (TMZ) in patients with metastatic malignant melanoma (MM).

被引：0
|
作者：
Plummer, R.
Lorigan, P.
Evans, J.
Steven, N.
Middleton, M.
Wilson, R.
Snow, K.
Dewji, R.
Calvert, H.
机构：
[1] No Ctr Canc Treatment, Newcastle Upon Tyne, Tyne & Wear, England
[2] Chrisite Hosp, Manchester, Lancs, England
[3] Western Infirm & Associated Hosp, Beatson Oncol Ctr, Glasgow G11 6NT, Lanark, Scotland
[4] Inst Canc Studies, Birmingham, W Midlands, England
[5] Canc Res UK, Oxford, England
[6] Queens Univ Belfast, Belfast, Antrim, North Ireland
[7] Pfizer GRD, Sandwich, Kent, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：456S / 456S
页数：1
相关论文
共 50 条
  • [41] A Phase I study of the poly-adp ribose polymerase (PARP) inhibitor, niraparib (NIR), in combination with irinotecan (IRN) in patients with advanced ewing sarcoma: results of sarc025 arm 2
    Zaki, K.
    Ballman, K. V.
    Hellman, L. J.
    Widemann, B. C.
    Hawkins, D. S.
    Mascarenhas, L.
    Glod, J. W.
    Ji, J.
    Zhang, Y.
    Geoerger, B.
    Whelan, J.
    Reinke, D.
    Patel, S. R.
    Chugh, R.
    Strauss, S. J.
    EUROPEAN JOURNAL OF CANCER, 2018, 103 : E30 - E30
  • [42] Phase I pharmacokinetic (PK) and pharmacodynamic (PD) evaluation of a small molecule inhibitor of poly ADP-ribose polymerase (PARP), KU-0059436 (Ku) in patients (p) with advanced tumours.
    Fong, P. C.
    Spicer, J.
    Reade, S.
    Reid, A.
    Vidal, L.
    Schellens, J. H.
    Tutt, A.
    Harris, P. A.
    Kaye, S.
    De Bono, J. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 126S - 126S
  • [43] First in human phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of KU-0059436 (KU), a small molecule inhibitor of poly ADP-RIBOSE polymerase (PARP) in cancer patients (P), including BRCA 1/2 mutation carriers
    de Bono, J.
    Boss, D.
    Fong, P.
    Roelvink, M.
    Yap, T.
    Tutt, A.
    Mortimer, P.
    O'Connor, M.
    Schellens, J. H.
    Kaye, S.
    ANNALS OF ONCOLOGY, 2007, 18 : 26 - 27
  • [44] Phase I study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the poly(ADP-ribose) polymerase (PARP) inhibitor veliparib (ABT-888; V) in combination with irinotecan (CPT-11; Ir) in patients (pts) with advanced solid tumors.
    LoRusso, P.
    Ji, J. J.
    Li, J.
    Heilbrun, K.
    Shapiro, G.
    Sausville, E. A.
    Boerner, S. A.
    Smith, D. W.
    Pilat, M. J.
    Zhang, J.
    Chen, A. P.
    Nechiporchik, N.
    Parchment, R. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [45] A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation
    Ruth Plummer
    Paul Lorigan
    Neil Steven
    Lucy Scott
    Mark R. Middleton
    Richard H. Wilson
    Evan Mulligan
    Nicola Curtin
    Diane Wang
    Raz Dewji
    Antonello Abbattista
    Jorge Gallo
    Hilary Calvert
    Cancer Chemotherapy and Pharmacology, 2013, 71 : 1191 - 1199
  • [46] TOPARP-B: A Phase II Randomised Trial of the Poly(ADP)-Ribose Polymerase (PARP) Inhibitor Olaparib for Metastatic Castration Resistant Prostate Cancers (mCRPC) with DNA Damage Repair (DDR) Alterations
    Mateo, Joaquin
    Porta, Nuria
    McGovern, Ursula
    Elliott, Tony
    Jones, Robert
    Syndikus, Isabel
    Ralph, Christy
    Jain, Suneil
    Varughese, Mohini
    Parikh, Omi
    Crabb, Simon
    Robinson, Angus
    McLaren, Duncan
    Birtle, Alison
    Tanguay, Jacob
    Miranda, Susana
    Seed, George
    Bertan, Claudia
    Espinasse, Aude
    Chatfield, Peter
    Bianchini, Diletta
    Hall, Emma
    Carreira, Suzanne
    De Bono, Johann
    BRITISH JOURNAL OF CANCER, 2019, 121 : 25 - 25
  • [47] A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation
    Plummer, Ruth
    Lorigan, Paul
    Steven, Neil
    Scott, Lucy
    Middleton, Mark R.
    Wilson, Richard H.
    Mulligan, Evan
    Curtin, Nicola
    Wang, Diane
    Dewji, Raz
    Abbattista, Antonello
    Gallo, Jorge
    Calvert, Hilary
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 71 (05) : 1191 - 1199
  • [48] First-in-class first-in-human phase 1 trial and translational study of the mono(ADP-ribose) polymerase-7 (PARP7) inhibitor RBN-2397 in patients with selected advanced solid tumors
    Yap, Timothy A.
    Cervantes, Andres
    Falchook, Gerald S.
    Patel, Manish R.
    Juric, Dejan
    Waqar, Saiama N.
    Schenk, Erin L.
    Shapiro, Geoffrey
    Boni, Valentina
    Perez, Cesar A.
    Burtness, Barbara
    Najjar, Yana G.
    Racca, Fabricio
    Rojas, Katerin
    Kuplast-Barr, Kristy
    McEachern, Kristen
    Samant, Manoj
    Bozon, Viviana
    Parasuraman, Sudha
    Johnson, Melissa
    CANCER RESEARCH, 2023, 83 (08)
  • [49] First in human phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of KU-0059436 (Ku), a small molecule inhibitor of poly ADP-ribose polymerase (PARP) in cancer patients (p), including BRCA1/2 mutation carriers
    Yap, T. A.
    Boss, D. S.
    Fong, P. C.
    Roelvink, M.
    Tutt, A.
    Carmichael, J.
    O'Connor, M. J.
    Kaye, S. B.
    Schellens, J. H.
    de Bono, J. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [50] First-in-human trial of a poly(ADP-ribose) polymerase (PARP) inhibitor MK-4827 in advanced cancer patients (pts) with antitumor activity in BRCA-deficient and sporadic ovarian cancers.
    Sandhu, S. K.
    Wenham, R. M.
    Wilding, G.
    McFadden, M.
    Sun, L.
    Toniatti, C.
    Stroh, M.
    Carpenter, C. L.
    De Bono, J. S.
    Schelman, W. R.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345